Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | MDM2 proto-oncogene, E3 ubiquitin protein ligase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | SWI:SNF matrix associated | 0.0013 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0013 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0013 | 0.5 | 0.5 | |
Trichomonas vaginalis | conserved hypothetical protein | 0.0013 | 0.5 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0013 | 0.5 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0013 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0013 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0013 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0013 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0013 | 0.5 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0013 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0013 | 0.5 | 0.5 |
Loa Loa (eye worm) | brahma associated protein | 0.0013 | 0.5 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0013 | 0.5 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0013 | 0.5 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0013 | 0.5 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0013 | 0.5 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0013 | 0.5 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.0013 | 0.5 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0013 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0013 | 0.5 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0013 | 0.5 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.0013 | 0.5 | 0.5 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0013 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.1 nM | Binding affinity to GST-thrombin-tagged human MDM2 (1 to 188) expressed in Escherichia coli assessed as inhibition of interaction with p53 in serum free buffer incubated for 20 mins prior to p53 addition measured after 60 mins by HTRF assay | ChEMBL. | 24601644 |
IC50 (binding) | = 1.8 nM | Binding affinity to GST-thrombin-tagged human MDM2 (1 to 188) expressed in Escherichia coli assessed as inhibition of interaction with p53 in buffer containing 15% human serum incubated for 20 mins prior to p53 addition measured after 60 mins by HTRF assay | ChEMBL. | 24601644 |
IC50 (functional) | = 15 nM | Cytotoxicity against human SJSA1 cells assessed as growth inhibition after 16 hrs by EdU incorporation assay in presence of 10% human serum | ChEMBL. | 24601644 |
IC50 (ADMET) | > 27 uM | Inhibition of CYP3A4 (unknown origin) using midazolam as substrate | ChEMBL. | 24601644 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 24601644 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.